Aura Biosciences Reports Second Quarter 2025 Financial Results and Business Highlights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 12 2025
0mins
Source: Globenewswire
Clinical Trials and Developments: Aura Biosciences is advancing its clinical programs, including the Phase 3 CoMpass trial for early choroidal melanoma and a Phase 1b/2 trial for non-muscle invasive bladder cancer (NMIBC), with plans to complete enrollment by late 2025. The company is also exploring additional ocular oncology indications and has filed a patent for a new formulation of bel-sar for bladder cancer.
Financial Position: Aura reported a cash position of $177.3 million as of June 30, 2025, sufficient to fund operations into the first half of 2027, despite an increase in research and development expenses and a net loss of $27 million for the second quarter.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
